EGFR is one of the most relevant genetic alteration in NSCLC, as it is targeted by tyrosine kinase inhibitors with a better side effect profile and an improved progression free survival as compared to standard chemotherapy [41]. Here, EGFR is linked to non-small cell lung carcinoma.